Current and emerging treatment options for uveal melanoma. - Wikidata - wikimedia - TriplyDB

Current and emerging treatment options for uveal melanoma.

Current and emerging treatment options for uveal melanoma.

http://www.wikidata.org/entity/Q34655878

about

Metastatic disease from uveal melanoma: treatment options and future prospects MicroRNA dysregulation in uveal melanoma: a new player enters the game Uveal Melanoma: Current Trends in Diagnosis and Management PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses.The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the Surveillance, Epidemiology, and End Results database (1973-2012)Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973-2012)In-depth proteomic profiling of the uveal melanoma secretome.Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.HIC1 modulates uveal melanoma progression by activating lncRNA-numb.Rare tumors: an eye on the future.Long noncoding RNA MALAT1 promotes uveal melanoma cell growth and invasion by silencing of miR-140.Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients.Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma.Long non-coding RNA FTH1P3 facilitates uveal melanoma cell growth and invasion through miR-224-5p.Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.Targeted silencing of the ADP-ribosyltransferase 3 gene inhibits the migration ability of melanoma cells.Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases

P2860

Q26738377-BB1B3826-F4AE-4348-AF3C-6FA11ABCFC4E Q27026746-1803C83D-7B01-4D6D-885F-3035F1A4E4EC Q28073924-4FAFDE68-1646-4963-AA19-C62CB8628B2D Q33902364-4E18E2EC-1563-4F2B-BBCD-E10B7065E7E2 Q34671157-4F35F63F-D451-4BA8-9AA5-E586485A55A5 Q37269087-7A58A65A-3145-4CBC-A797-D46394C855B5 Q37381397-DDFFC985-CFC1-48FD-893C-7CD15E58FA38 Q37573466-10E29B3B-17F3-488E-A6F2-AEFB4AC65DCC Q37580290-66CE1BEA-5A81-4CBE-8016-219138DF6BA5 Q38646057-848BAD92-2C8A-416C-AD81-E6A30B9900DF Q38736921-5B758279-92EA-45FE-A33C-AF4FA64CF124 Q38966454-972A0B47-D128-4384-8A73-7521A71EF3F3 Q41210332-1FB5F312-4C43-4270-B7DB-81FA4945BDEF Q43110773-9E06B547-738B-4D23-94EF-460DD3904900 Q43181572-024FA19F-47D3-4A42-9B01-9CF8899352D9 Q45216227-34C0CE10-AC65-47EB-B424-53CB672B04C7 Q50057781-BE1B41B9-5428-4784-83D5-D2A4AA52EAA5 Q55027942-473F2242-BB00-4CAF-8B79-C108A33CF2CD Q57317466-258931CA-60E7-4402-B3D3-64DF4FE9AA97

P2860

Current and emerging treatment options for uveal melanoma.

http://www.wikidata.org/entity/Q34655878

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Current and emerging treatment options for uveal melanoma.

@ast

Current and emerging treatment options for uveal melanoma.

@en

Current and emerging treatment options for uveal melanoma.

@nl

type

label

Current and emerging treatment options for uveal melanoma.

@ast

Current and emerging treatment options for uveal melanoma.

@en

Current and emerging treatment options for uveal melanoma.

@nl

prefLabel

Current and emerging treatment options for uveal melanoma.

@ast

Current and emerging treatment options for uveal melanoma.

@en

Current and emerging treatment options for uveal melanoma.

@nl

P1433

Q34655878-A6F2F99C-C23C-44A4-A962-2E0886379476

P1476

Q34655878-496270C6-3624-46FD-9D9F-38BCFFD3DB38

P2093

Q34655878-24843ABA-E95C-46F4-A230-4F100D8A8C8A

Q34655878-4A59F427-26C9-495E-8D8D-7F99939ADBDB

Q34655878-563F4091-2EC4-4CD9-969F-B77AE4645AF2

Q34655878-7D457393-7EE7-443F-BE9B-077403AF6695

Q34655878-87C50E7C-3444-49AF-80B6-14D46AFCB5BF

Q34655878-A65E518F-55B2-46D4-B7A4-BE597E83BA67

Q34655878-DAF1E47A-DF50-46F9-BE46-87A4AD2EADE8

Q34655878-E239F591-8C8D-46FC-BD8C-6AB8E83E676B

Q34655878-ED898139-8A4D-40E7-A0A9-683A287ECAF8

P2860

Q34655878-038B971E-F9F8-4ED7-AEE8-0BB65308EC41

Q34655878-06F7F98E-732D-4FCE-92FB-E22473FF8828

Q34655878-07A475FC-69D1-41ED-828B-FCE62841B4BC

Q34655878-07BCCE0A-A1EA-4DE2-9B62-5F6357970FD7

Q34655878-08E6A165-9B2C-4D61-9ED5-0113527EC3EB

Q34655878-11E23C06-B5EF-4B46-9994-9713548CC0B5

Q34655878-13E4895D-90BF-437D-9538-2FE0ACA14F99

Q34655878-1DC2C1B3-8D89-4103-A33C-CD0D85C3876F

Q34655878-1E8B003D-19AC-44CC-BC8C-545B6267DA72

Q34655878-2099A779-DAF6-4892-86D5-F9DBEEFD00BA

P304

Q34655878-E8E3DC2C-83AC-49C4-8E2D-AFBEB0F0153B

P31

Q34655878-1A174C0C-8950-42AE-ABFD-EEB930E260E0

P356

Q34655878-F0D9EE75-8720-42D2-8839-73741401F500

P407

Q34655878-C8B5F14A-4CE5-4CEF-A254-9F75B8452C17

P478

Q34655878-FFF90A64-4F46-4747-B18C-89F0B3D8C965

P577

Q34655878-9AD70CFF-B2E7-49ED-8F60-3648C5E73224

P698

Q34655878-5BED0739-9D7A-4731-A067-2AFB4D2AC3F9

P932

Q34655878-92322840-CCB3-43F0-8B3C-74A1971CBB47

P356

P1433

Clinical Ophthalmology

P1476

Current and emerging treatment options for uveal melanoma.

@en

P2093

Alexandre Nakao Odashiro

http://www.w3.org/2001/XMLSchema#string

Cristina Miyamoto

http://www.w3.org/2001/XMLSchema#string

Dominique F De Souza

http://www.w3.org/2001/XMLSchema#string

Li-Anne Lim

http://www.w3.org/2001/XMLSchema#string

Macanori Odashiro

http://www.w3.org/2001/XMLSchema#string

Miguel N Burnier

http://www.w3.org/2001/XMLSchema#string

Patricia Rusa Pereira

http://www.w3.org/2001/XMLSchema#string

Paula L Blanco

http://www.w3.org/2001/XMLSchema#string

Shawn Maloney

http://www.w3.org/2001/XMLSchema#string

P2860

The role of c-kit and imatinib mesylate in uveal melanoma.

Metastatic uveal melanoma: biology and emerging treatments

Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Direct tumor damage mechanisms of photodynamic therapy.

Adjuvant indocyanine green in transpupillary thermotherapy for choroidal melanoma.

Subthreshold transpupillary thermotherapy in management of foveal subretinal fluid in small pigmented choroidal lesions.

Transpupillary thermotherapy: results in 50 patients with choroidal melanoma.

P304

1669-1682

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OPTH.S28863

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24003303

http://www.w3.org/2001/XMLSchema#string

P932

3755706

http://www.w3.org/2001/XMLSchema#string